These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34650351)

  • 21. Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies.
    Sun M; Dubé MP; Hennessy T; Schultz CJ; Barhdadi A; Rhainds D; Hillis GS; Tardif JC
    Int J Cardiol; 2022 Sep; 363():20-22. PubMed ID: 35716932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
    Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canakinumab and cardiovascular outcomes: results of the CANTOS trial.
    Shah SR; Abbasi Z; Fatima M; Ochani RK; Shahnawaz W; Asim Khan M; Shah SA
    J Community Hosp Intern Med Perspect; 2018; 8(1):21-22. PubMed ID: 29441161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
    Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Inflammation After Myocardial Infarction.
    Mahtta D; Sudhakar D; Koneru S; Silva GV; Alam M; Virani SS; Jneid H
    Curr Cardiol Rep; 2020 Aug; 22(10):110. PubMed ID: 32770365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammation and ischemic heart disease: The next therapeutic target?
    Vilela EM; Fontes-Carvalho R
    Rev Port Cardiol (Engl Ed); 2021 Oct; 40(10):785-796. PubMed ID: 34857118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colchicine: an affordable anti-inflammatory agent for atherosclerosis.
    Thompson PL; Nidorf SM
    Curr Opin Lipidol; 2018 Dec; 29(6):467-473. PubMed ID: 30320614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.
    Hennessy T; Soh L; Bowman M; Kurup R; Schultz C; Patel S; Hillis GS
    Am Heart J; 2019 Sep; 215():62-69. PubMed ID: 31284074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colchicine in the Management of Acute and Chronic Coronary Artery Disease.
    Bouabdallaoui N; Tardif JC
    Curr Cardiol Rep; 2021 Jul; 23(9):120. PubMed ID: 34269908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.
    Zomer E; Liew D; Tonkin A; Trauer JM; Ademi Z
    Int J Cardiol; 2019 Jun; 285():1-5. PubMed ID: 30686493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammation and ischemic heart disease: The next therapeutic target?
    Vilela EM; Fontes-Carvalho R
    Rev Port Cardiol (Engl Ed); 2021 Aug; ():. PubMed ID: 34456098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
    Ridker PM; Everett BM; Pradhan A; MacFadyen JG; Solomon DH; Zaharris E; Mam V; Hasan A; Rosenberg Y; Iturriaga E; Gupta M; Tsigoulis M; Verma S; Clearfield M; Libby P; Goldhaber SZ; Seagle R; Ofori C; Saklayen M; Butman S; Singh N; Le May M; Bertrand O; Johnston J; Paynter NP; Glynn RJ;
    N Engl J Med; 2019 Feb; 380(8):752-762. PubMed ID: 30415610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
    Everett BM; Cornel JH; Lainscak M; Anker SD; Abbate A; Thuren T; Libby P; Glynn RJ; Ridker PM
    Circulation; 2019 Mar; 139(10):1289-1299. PubMed ID: 30586730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combating Inflammation in Cardiovascular Disease.
    Sethwala AM; Goh I; Amerena JV
    Heart Lung Circ; 2021 Feb; 30(2):197-206. PubMed ID: 33039279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials.
    Adamstein NH; MacFadyen JG; Rose LM; Glynn RJ; Dey AK; Libby P; Tabas IA; Mehta NN; Ridker PM
    Eur Heart J; 2021 Mar; 42(9):896-903. PubMed ID: 33417682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
    Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
    Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?
    Whayne TF
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):1-10. PubMed ID: 32356107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
    N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.
    Zhang FS; He QZ; Qin CH; Little PJ; Weng JP; Xu SW
    Acta Pharmacol Sin; 2022 Sep; 43(9):2173-2190. PubMed ID: 35046517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.